Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Acquisitions & Divestments (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Change in Acquisitions & Divestments for 12 consecutive years, with $77.8 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Acquisitions & Divestments fell 25.7% year-over-year to $77.8 million; the TTM value through Mar 2026 reached $459.1 million, up 22.77%, while the annual FY2025 figure was $486.0 million, 44.1% up from the prior year.
  • Change in Acquisitions & Divestments hit $77.8 million in Q1 2026 for Syndax Pharmaceuticals, down from $144.8 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $154.9 million in Q2 2023 and bottomed at $50.4 million in Q1 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $99.0 million, with a median of $103.0 million recorded in 2025.
  • Year-over-year, Change in Acquisitions & Divestments skyrocketed 149.45% in 2022 and then crashed 60.14% in 2024.
  • Syndax Pharmaceuticals' Change in Acquisitions & Divestments stood at $113.2 million in 2022, then dropped by 0.22% to $113.0 million in 2023, then fell by 5.01% to $107.3 million in 2024, then soared by 34.85% to $144.8 million in 2025, then crashed by 46.27% to $77.8 million in 2026.
  • According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $77.8 million, $144.8 million, and $103.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.